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Background—The purpose of this study was to examine the prevalence of abnormalities in cardiac structure and function
present in patients with heart failure and a preserved ejection fraction (HFPEF) and to determine whether these
alterations in structure and function were associated with cardiovascular morbidity and mortality.
Methods and Results—The Irbesartan in HFPEF trial (I-PRESERVE) enrolled 4128 patients; echocardiographic
determination of left ventricular (LV) volume, mass, left atrial (LA) size, systolic function, and diastolic function were
made at baseline in 745 patients. The primary end point was death or protocol-specific cardiovascular hospitalization.
A secondary end point was the composite of heart failure death or heart failure hospitalization. Associations between
baseline structure and function and patient outcomes were examined using univariate and multivariable Cox
proportional hazard analyses. In this substudy, LV hypertrophy or concentric remodeling was present in 59%, LA
enlargement was present in 66%, and diastolic dysfunction was present in 69% of the patients. Multivariable analyses
controlling for 7 clinical variables (including log N-terminal pro-B–type natriuretic peptide) indicated that increased LV
mass, mass/volume ratio, and LA size were independently associated with an increased risk of both primary and heart
failure events (all P0.05).
Conclusions—Left ventricular hypertrophy or concentric remodeling, LA enlargement, and diastolic dysfunction were
present in the majority of patients with HFPEF. Left ventricular mass and LA size were independently associated with
an increased risk of morbidity and mortality. The presence of structural remodeling and diastolic dysfunction may be
useful additions to diagnostic criteria and provide important prognostic insights in patients with HFPEF.
Clinical Trial Registration— http://www.clinicaltrials.gov. Unique identifier: NCT00095238.
(Circulation. 2011;124:2491-2501.)
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Patients with heart failure and a reduced ejection fractionexhibit progressive left ventricular (LV) dilation, eccen-
tric remodeling, and systolic dysfunction.1,2 These pathophys-
iological changes in cardiac structure and function have been
closely associated with increased morbidity and mortality.1,2
Treatments that result in the reversal of these structural and
functional changes also result in reduced morbidity and
mortality in patients with heart failure and a reduced ejection
fraction.1,2 By contrast, the pathophysiology underlying the
development of heart failure with a preserved ejection frac-
tion (HFPEF) remains incompletely defined.3,4 A comprehen-
sive examination of cardiac structure and function and its
association with morbidity and mortality is an important and
necessary step toward meeting deficiencies in the areas of
diagnosis, prognosis, and treatment in patients with HFPEF.
Clinical Perspective on p 2501
The diagnosis of HFPEF is largely made by exclusion of
patients with increased LV volume and reduced ejection
fraction.4,5 Diagnostic criteria may be improved by the
addition of inclusion criteria that also reflect assessment of
cardiac structure and function. In addition, defining the
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relationships between structural remodeling, changes in func-
tion, and clinical outcomes may provide prognostic informa-
tion. With these data, studies could be developed to test the
hypothesis that the reversal of the changes in LV structure
and function would result in reduced morbidity and mortality
in patients with HFPEF.
We conducted a large echocardiographic substudy in pa-
tients with HFPEF as part of the Irbesartan in Heart Failure
With Preserved Ejection Fraction (I-PRESERVE) trial. The
purpose of this echocardiographic substudy was to examine
the type and prevalence of changes in cardiac structure and
function present in patients with HFPEF and to determine
whether these changes in structure and function are associ-
ated with alterations in morbidity and mortality.
Methods
Study Design
The I-PRESERVE trial enrolled 4128 patients; the geographic
distribution of enrolled patients was presented in a previous publi-
cation6; 745 of these patients were also enrolled in an echocardio-
graphic substudy in which each patient underwent 2-dimensional
echocardiography and Doppler and tissue Doppler studies before
randomization. To be enrolled in the echocardiographic substudy,
patients had to fulfill all inclusion and exclusion criteria for the
I-PRESERVE trial.6,7 Inclusion criteria included age 60 years, left
ventricular ejection fraction 45%, and recent hospitalization for
heart failure or moderate to severe symptoms and corroborative
objective evidence of heart failure or a cardiac substrate for diastolic
dysfunction that could include any one of the following: chest x-ray,
evidence of pulmonary congestion, a LBBB on ECG, echocardio-
graphic evidence of increased wall thickness, or increased left atrial
(LA) diameter. For the current echocardiographic substudy, patients
had to be in normal sinus rhythm and have an echocardiographic
study of adequate quality. Patients with a previous history of atrial
fibrillation were not excluded as long as they were in normal sinus
rhythm at time of enrollment. Table 1 provides data on the number
of patients who had a previous history of atrial fibrillation.
The primary outcome for I-PRESERVE was death from any cause
or hospitalization for a protocol-specified cardiovascular cause:
hospitalization for worsening heart failure, myocardial infarction,
stroke, unstable angina, or ventricular or atrial dysrhythmia.7 One
secondary outcome was a composite heart failure outcome consisting
of death due to heart failure or hospitalization due to worsening heart
failure. Deaths and hospitalizations were adjudicated by members of
an independent end-point committee whose members were unaware
of study-group assignments and used prespecified criteria.8
Echocardiographic Study
Echocardiograms were performed using a standardized protocol and
standard methods of acquisition as described by the American
Association of Echocardiography.9–11 Left ventricular mass was
calculated using the Devereux method, and LV volume was calcu-
lated using the area of discs method.9–11 All echocardiograms were
analyzed at the echocardiography core laboratory at the University of
Maryland directed by John Gottdiener, MD.
Structure
The presence of LV dilation was determined using a partition value
of LV end-diastolic volume 90 mL/m2.12 The presence of LV
hypertrophy (LVH) was determined using partition values of LV
mass indexed to height2.749.2 g/m2.7 for men and46.7 g/m2.7 for
women.10 In addition, as a secondary analysis, the presence of LVH
was determined using partition values of LV mass indexed to body
surface area 115 g/m2 for men and 95 g/m2 for women.10 In
patients without LVH, concentric remodeling was defined as relative
wall thickness 0.42 and/or LV mass/end-diastolic volume ratio
(M/V) 1.75.10 Left atrial size was categorized as mildly enlarged if
LA area was 20 to 30 cm2 and moderately-to-severely enlarged if LA
area was 31 cm2.10
Systolic Properties
Stroke work was used as an index of LV systolic performance.13,14
Indices of LV systolic function included LV fractional shortening,
ejection fraction, stroke volume, cardiac output, preload recruitable
stroke work, and systolic myocardial long-axis shortening velocity
(S).13,14 Single-beat end-systolic elastance was used as an index of
LV contractility; effective arterial elastance was calculated as end-
systolic pressure/stroke volume.13,14
Diastolic Properties
Isovolumic relaxation time was used as an index of isovolumic
pressure decline. Diastolic filling was assessed using transmitral
flow velocities (E, A); myocardial long-axis lengthening velocity
was assessed (E). Pulmonary capillary wedge pressure (PCWP) was
estimated using the equation: PCWP1.3[E/E]2 and was used to
reflect ambient or instantaneous diastolic pressure; LA area was used
to reflect chronic changes in diastolic pressure. The grade of
diastolic dysfunction was determined using a previously pub-
lished method.15 Right ventricular systolic pressure
(RVSP, mm Hg) was estimated using Doppler tricuspid regurgi-
tant velocity (V) as RVSP4(V2)10 mm Hg.
Statistical Analyses
All data are presented as meanSD. Comparisons of baseline
characteristics for patients in the echocardiographic cohort versus the
remaining study cohort were examined using 2-sided Student t tests,
Wilcoxon rank sum tests, or Fisher exact tests determined by
variable type and distributional shape. To correct for the large
number of comparisons made, statistically significant difference was
defined as one in which the P value was 0.001. This conservative
approach was equivalent to a Bonferroni correction for 50 compar-
isons. The prevalence of abnormalities in cardiac structure and
function was estimated as the proportion of occurrence of each
characteristic out of the substudy cohort. Normal ranges and partition
values for limits of normal were obtained from echocardiographic
core labs and the American Society of Echocardiography.9,10,12,14,16
Univariate and multivariable Cox proportional hazards analyses were
conducted to examine associations between outcome and continuous
echocardiographic measures and to compare the clinical event rates
in patients with or without specific echocardiographic characteris-
tics. The assumptions of proportional hazards and linearity of the
hazard ratios for continuous variables were assessed and found to be
sufficiently met for each Cox proportional hazard model. Included in
the multivariable Cox proportional hazards analysis were 7 clinical
covariates (log N-terminal pro-B–type natriuretic peptide, age, dia-
betes mellitus, hospitalization for heart failure within 6 months
preceding randomization, chronic lung disease, neutrophils, and
ejection fraction) determined to be predictive of the primary and
heart failure outcomes from the I-PRESERVE trial. The Kaplan-
Meier cumulative event rate and survival curves were not covariate
adjusted.
The overall trial and the echocardiographic substudy were ap-
proved by the ethics committee at each participating center and
patients provided written informed consent. The Executive Commit-
tee, study sponsors, Steering Committee, Statistical Data Analysis
Center were previously described.6,7 This manuscript was prepared
and submitted for publication by the Executive Committee, and
echocardiographic core laboratory director all of whom had unre-
stricted access to the study data and vouch for the accuracy and
completeness of the reported analyses.
Results
Demographic Characterization
The echocardiographic substudy participants represented
18% of the total I-PRESERVE enrollment. There were no
clinically relevant differences between the echocardiographic
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Table 1. Baseline Characteristics of Patients in the Echo Substudy vs Remaining Study Cohort
Echo Cohort (n745) Study Cohort (n3383) P
Demographic characteristics
Age
MeanSD, y 727 727 0.450
75 y, n (%) 265 (36) 1148 (34) 0.394
Female sex, n (%) 459 (62) 2032 (60) 0.457
Race, n (%) 0.005
White 713 (96) 3146 (93)
Black 12 (2) 70 (2)
Asian 0 (0) 34 (1)
Other 20 (3) 132 (4)
Clinical characteristics
NYHA class, n (%) 0.790
II 164 (22) 706 (21)
III 560 (75) 2584 (76)
IV 21 (3) 91 (3)
Heart rate, meanSD, bpm 7010 7210 0.001
Blood pressure, meanSD, mm Hg
Systolic 13615 13615 0.994
Diastolic 799 799 0.960
Body–mass index 305 305 0.418
Electrocardiographic findings, n (%)
Left ventricular hypertrophy 210 (28) 1050 (31) 0.135
Left bundle-branch block 48 (6) 288 (9) 0.064
Ejection fraction, meanSD, % 0.600.09 0.590.09 0.019
Cause of heart failure, n (%)
Ischemia 150 (20) 886 (26) 0.007
Hypertension 529 (71) 2093 (62) 0.030
HF Hospitalization within previous 6 mo, n (%) 308 (41) 1508 (45) 0.112
Medical history, n (%)
Hypertension 683 (92) 2967 (88) 0.002
Angina symptoms 277 (37) 1375 (41) 0.083
Unstable angina 58 (8) 257 (8) 0.879
Myocardial infarction 148 (20) 821 (24) 0.010
PCI or CABG 98 (13) 450 (13) 0.952
Artial fibrillation 192 (26) 1017 (30) 0.021
Diabetes mellitus 187 (25) 947 (27) 0.113
Stroke or transient ischemic attack 77 (12) 322 (11) 0.494
Quality of life
Score on the Minnesota Living with Heart Failure scale
Median 40 43 0.001
Interquartile range 27–54 28–59
Laboratory measurements
Hemoglobin
MeanSD, g/dL 142 142 0.640
Anemia, n (%) 76 (11) 438 (13) 0.049
Creatinine, meanSD, mg/dL 0.990.31 10.34 0.497
(Continued)
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substudy patients and the remaining I-PRESERVE study
cohort (Table 1).
Structure
The mean values of LV end diastolic dimension and volume
were within the normal range (Table 2). Approximately 3.5%
of the patients exceeded the upper limit partition value for LV
end diastolic volume of 90 mL/m2.
The mean values of LV mass and the mass/volume ratio
were increased above the normal range (Table 2). Using
partition values of LV mass indexed to height2.7, LVH was
present in 29% and concentric remodeling was present in an
additional 25% by relative wall thickness or 30% by M/V
(Figure 1). Using partition values of LV mass indexed to
BSA, LVH was present in 20% and concentric remodeling
was present in an additional 29% by relative wall thickness or
35% by M/V. Therefore, 54% to 59% had LVH or LV
concentric remodeling.
Left atrial area was increased in 66% of the patients. Of
those, the LA enlargement was mild in 51% and moderate to
severe in 15% (Figure 1).
Function
The mean values for all of the indices of LV systolic chamber
properties were within the normal range (Table 2). A minority
had values less than the lower limit for example, EF was
50% in 7%. Using a partition value of 6.0 cm/s, S was
abnormal in 14%.
End-systolic elastance normalized by the M/V ratio was
1.980.99 mm Hg/g and was within the normal range of 1.2
to 2.0 mm Hg/g. In addition, the Ees/Ea ratio was within the
normal range.
Taken together, indices of LV diastolic chamber properties
indicated that 31% of the patients were normal, 29% had mild
grade 1 diastolic dysfunction (impaired relaxation), 36% had
moderate grade 2 diastolic dysfunction (pseudonormal), and
4% had severe grade 3 diastolic dysfunction (restrictive
pattern; Table 2, Figure 1).
Relationship Between Cardiac Structure and
Function and Primary Study End Point
The primary end point occurred in the echocardiographic
substudy at a rate comparable to the occurrence of the
primary end point in the I-PRESERVE study cohort as a
whole.7 In the overall I-PRESERVE study cohort. There were
103 primary end points per 1000 patient-years, and the
primary end point occurred in 36% of the randomized
patients. In the echocardiographic substudy, there were 96
primary end points per 1000 patient-years and the primary
end point occurred in 32%.
There was a significant association between LV mass, LV
geometry, LA area, diastolic dysfunction (specifically grade
3), RVSP, and the occurrence of the primary end point in the
univariate analysis. In the multivariable analysis, there was a
significant association between continuous LV mass, categor-
ical LVH, continuous LV Mass/Volume, categorical LA
enlargement, and the occurrence of the primary end point
(Table 3). For example, for a 10 U (g/m2) increase in LV
mass/ht2.7 there was a 19% increase in the rate of an
occurrence of the primary event (P0.001). There was no
Table 1. Continued
Echo Cohort (n745) Study Cohort (n3383) P
Estimated glomerular filtration rate
MeanSD, mL  min1  1.73 m2 of BSA 72.321.6 72.622.7 0.738
60 mL  min1  1.73 m2, n (%) 222 (31) 1023 (31) 0.929
Potassium, mmol/L 4.40.4 4.50.5 0.060
NT-proBNP, pg/mL
Median 298 352 0.058
Interquartile range 129–915 136–976
Medications, n (%)
Diuretic 598 (83) 2725 (83) 0.783
Loop 361 (60) 1718 (63) 0.233
Thiazide 306 (51) 1224 (45) 0.014
Spironolactone 120 (20) 501 (18) 0.395
ACE inhibitor 221 (37) 785 (29) 0.001
Digoxin 62 (10) 482 (18) 0.001
-blocker 455 (76) 1905 (70) 0.017
Antiarrhythmic drug 57 (9) 294 (11) 0.384
Calcium-channel blocker 318 (53) 1271 (47) 0.010
Nitrate 169 (28) 904 (33) 0.020
Oral anticoagulant 114 (19) 650 (24) 0.012
Antiplatelet 423 (70) 1925 (71) 0.933
Lipid-lowering agent 214 (36) 1017 (37) 0.476
NT-proBNP indicates N-terminal pro brain natiuretic peptide; NYHA, New York Heart Association class; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass graft; BSA, body surface area; and ACE, angiotensin-converting enzyme.
2494 Circulation December 6, 2011
 by guest on June 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
relationship with categorical diastolic dysfunction (grade
1–3). There were no significant associations between E,
E/A, E, E/E, IVRT, or DT and the occurrence of the
primary end point or the heart failure end point examined
in the multivariate analysis. Complete data are presented in
the online-only Data Supplement. The Kaplan-Meier
curves shown in Figure 2 demonstrate that the cumulative
event rate was higher in patients with LVH, LA enlarge-
ment, or grade 3 diastolic dysfunction. Kaplan-Meier
curves plotting survival are presented in the online-only
Data Supplement.
Relationship Between Cardiac Structure and
Function and Heart Failure End Point
The heart failure end point occurred in the echocardiographic
substudy at a rate comparable to the occurrence of the heart
failure end point in the I-PRESERVE study cohort as a
whole.7 In the I-PRESERVE study cohort, there were 47
heart failure end points per 1000 patient-years and the heart
failure end point occurred in 17% of the randomized patients.
In the echocardiographic substudy, there were 41 heart failure
end points per 1000 patient-years and the heart failure end
point occurred in 14%.
There were significant associations among LV mass, LV
geometry, LA area, diastolic dysfunction (specifically grade
3), RVSP, and the occurrence of the heart failure end point in
the univariate analysis. In the multivariable analysis, there
was a significant association between continuous LV mass,
categorical LVH, continuous M/V ratio, continuous LA area,
and categorical LA enlargement and the occurrence of the
heart failure end point (Table 3). For example, for a 1-U
(cm2) increase in LA area, there was a 3.6% increase in the
rate of a heart failure event (P0.05). There was a 226%
increase in the risk of a heart failure event for those who had
LA enlargement compared with those who did not (P0.05).
The Kaplan-Meier curves shown in Figure 2 demonstrate that
the cumulative event rate for the heart failure outcome was
increased in patients with LVH, LA enlargement, or Grade 3
diastolic dysfunction. Kaplan-Meier curves plotting survival
are presented in the online-only Data Supplement.
Discussion
There were 2 principal findings of the I-PRESERVE echo-
cardiographic substudy. First, our patients with HFPEF had a
high prevalence of structural remodeling characterized by
significant concentric LV remodeling and LVH and a high
prevalence of diastolic dysfunction as evidenced both by
abnormal echocardiographic-Doppler indices and increased
LA area. Second, the presence of these changes in structure
and function was independently associated with an increased
risk of morbidity and mortality. This risk remained signifi-
cantly elevated even after known risk factors, including
N-terminal pro-B–type natriuretic peptide, were included in
the multivariable analysis. These findings may be pivotal to
the development of improved diagnostic criteria and prog-
nostic assessment of patients with HFPEF. In addition, these
findings may enhance our understanding of the pathophysi-
ology underlying the clinical heart failure in these patients.
Structural Remodeling
Left ventricular structural remodeling is characterized by
quantitation of LV mass, volume, and geometry. It is impor-
tant to recognize that even when LVH is not present,
cardiomyocyte cellular hypertrophy can still occur, LV mass
can be increased compared to a patient’s preexisting baseline,
and LV mass can be increased relative to LV volume. It is
likely that the observed substantial prevalence of concentric
remodeling reflects these changes even in the absence of
LVH.
Patients with HFPEF have clinical characteristics that
place them at substantial risk for developing LVH and
Table 2. Echocardiographic Data
Echo Cohort Normal Range
LV structure
End-diastolic dimension, cm 4.80.6 4.0–6.0
End-diastolic volume, mL,
mL/m2
9428, 4914 80–180, 40–90
End-systolic dimension, cm 3.20.7 2.0–4.0
End-systolic volume, mL, mL/m2 3519, 189 25–50, 15–25
Wall thickness, cm 0.930.15 0.8–0.9
Mass, g, g/ht2.7 16448, 4312 80–140, 18–38
Relative wall thickness 0.400.08 0.36–0.40
Mass/EDV, g/mL 1.950.80 1.25–1.75
LV systolic properties
Fractional shortening, % 4310 30–45
Ejection fraction, % 649 55–75
Stroke volume, mL 5924 50–70
Cardiac output, L/min 3.91.6 3.5–5.0
S, lateral, cm/sec 8.22.3 6–14
Stroke work, kg  cm 6.73.0 5–10
Preload recruitable stroke work,
kg/cm2
9027 75–125
Ees, mm Hg/mL 3.62.0 1.2–3.0
Ea, mm Hg/mL 1.90.8 1.2–1.8
LV diastolic properties
E, cm/sec 7828 40–90
A, cm/sec 8326 40–100
E/A 1.050.74 0.6–1.4
E lateral annulus, cm/sec 9.13.4 7.0–11.5
E septal annulus, cm/sec 7.22.9 5.0–11.0
E/E lateral 10.04.5 4.5–11.5
PCWP, mm Hg 156 5–12
IVRT, ms 9522 60–130
E deceleration time, ms 21677 185–310
Left atrial area, cm2, cm2/m2 236, 123 10–20, 5–10
RV systolic pressure 3713 15–25
Values are meanSD unless otherwise indicated. Normal Range is adjusted
for the average age of the echo cohort (70 years).
EDV indicates end-diastolic volume; DT, mitral valve deceleration time; IVRT,
isovolumic relaxation time; E, peak early diastolic filling velocity; A, peak late
diastolic filling velocity during atrial contraction; E, mitral lateral and septal
annular tissue velocity during early filling; S, mitral lateral annular tissue
velocity during systole; Ees, end-systolic elastance; Ea, arterial elastance;
PCWP, pulmonary capillary wedge pressure; and RV, right ventricle.
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concentric remodeling.7,13–15,17–25 For example, HFPEF pa-
tients are older, more often women, have a high prevalence of
hypertension, and a large number of comorbidities, each of
which increase the risk for developing concentric remodeling.
However, the prevalence of LVH and concentric remodeling
in the current study was at least as high as would be expected
on the basis of the presence of these characteristics alone.
Previous smaller studies of unselected patients support this
finding.18,19
In HFPEF patients, a variety of risk factors may contribute
to the resultant morbidity and mortality rates. These include
underlying disease processes such as hypertension and dia-
betes mellitus, age, sex, and other comorbidities. However,
the heart failure morbidity in I-PRESERVE (heart failure
hospitalization rate of 47/1000 patient years) was substan-
tially higher than that observed in recent hypertension and
diabetes studies (heart failure hospitalization rate of 2.5–11.5/
1000 patient years).26–33 Data from the current study, fully
adjusted for other important covariates, suggests that the
presence of structural remodeling, particularly LVH, in
HFPEF patients is associated with and may contribute mecha-
nistically to an increased risk of morbidity and mortality.
One consequence of using data from a randomized clinical
trial to characterize changes in structure (discussed above)
and function (discussed below) is the lack of a control group
from which to derive normal ranges and normal limit parti-
tion values. We used normal ranges and partition values taken
from echocardiographic core laboratories, consensus guide-
lines from the American Society of Echocardiography, and
other published studies.9,10,12,14,16 The ranges and partition
values chosen were adjusted for age and sex. The analyses
based on these normal ranges added important insights and
provided important context for interpretation. Despite the
care taken in these choices, statistical comparisons would be
improved by using a simultaneously enrolled cohort with
comparable age, sex, race, geographical distribution, and
comorbidity profile.
Diastolic Properties
In the current echocardiographic substudy, the presence of
diastolic dysfunction was assessed using indices of LV
pressure decline, filling, and distensibility. These indices
were used in combination to determine the grade or severity
of diastolic dysfunction and to estimate ambient LV diastolic
filling pressure.15 In addition, changes in LA size were used
to evaluate LV diastolic pressure and integrate changes in LV
diastolic pressure over time. That is, even when ambient LV
diastolic pressures are normal, an increased LA size reflects
the length and severity of the increased LV diastolic pressure
over time.
The same demographic and clinical characteristics that
place patients with HFPEF at high risk of developing struc-
tural remodeling also increase the likelihood of developing
diastolic dysfunction. However, the prevalence of diastolic
dysfunction in the current study was higher than would be
expected on the basis of the presence of these clinical
characteristics alone.15,20,30 For example, in cross-sectional
population studies of patients with age 65 years, diastolic
dysfunction was present in 15% to 30%.11 In older patients
with hypertension, coronary artery disease, and/or diabetes
mellitus, the prevalence of diastolic dysfunction was 50% to
60%.26–33 The highest prevalence however is in patients with
symptomatic heart failure, particularly patients with HFPEF.
Data from the current study are concordant with previous
HFPEF studies, which have shown that the prevalence of
diastolic dysfunction approaches 70%.17–25 In these previous
studies, morbidity and mortality events were higher in pa-
tients with diastolic dysfunction as measured by echocardio-
graphic parameters or LA size. However, in the current study,
echocardiographic and Doppler indices of diastolic dysfunc-
tion did not have significant prognostic value and were not
associated with an increase in cardiovascular events. By
contrast, LA enlargement did have significant prognostic
value. The apparent discrepancy between prognostic value of
Figure 1. A, Prevalence of concentric
remodeling using relative wall thickness cri-
teria and LVH using sex-specific partition
values of LV mass indexed to height.2.7 In
patients with HFPEF, the prevalence of LVH
was 29% and that of concentric remodeling
was 25%. B, Prevalence of concentric
remodeling using M/V criteria and LVH. In
patients with HFPEF, the prevalence of LVH
was 29%, and that of concentric remodeling
was 30%. Thus, the majority of HFPEF
patients had LV structural remodeling. C,
Prevalence LA enlargement. In patients with
HFPEF, the prevalence of LA enlargement
was 66%. Because LA size reflects LV dia-
stolic pressure integrated over time, these
data indicate that the majority of HFPEF
patients had increased diastolic pressure. D,
Prevalence of diastolic dysfunction classified
by grade 1 to 3. In patients with HFPEF, the
prevalence of diastolic dysfunction was
69%. Thus, the majority of HFPEF patients
had diastolic dysfunction. LVH indicates left
ventricular hypertrophy; LV, left ventricular;
RWT, relative wall thickness; and M/V, LV
mass/end-diastolic volume ratio.
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LA size and Doppler indices and the differences with previ-
ous studies may have a number of explanations. Changes in
LA size result from both the extent and duration of increased
LV diastolic pressure (ie, the integrated area under the
pressure-versus-time relationship). By contrast, Doppler and
tissue Doppler indices such as E, E, and the E/E ratio
represent LV diastolic pressures at 1 point in time and are
very sensitive to changes in LV load. Because all of the
Table 3. Association Between Baseline Cardiac Structure and Function and Clinical Outcomes
Primary End Point
Variable
Univariate Analysis Multivariable Analysis*
Event Rate,
per 1000 Patient y HR (95% CI) P HR (95% CI) P
LV mass/HT2.7
Per 1-unit increase 1.028 (1.019–1.037) 0.001 1.019 (1.009–1.029) 0.001
LV hypertrophy
No 76.1 Reference Reference
Yes 143.0 1.860 (1.404–2.464) 0.001 1.589 (1.168–2.161) 0.003
LV mass/volume ratio
Per 1-unit increase 1.265 (1.070–1.496) 0.006 1.296 (1.074–1.564) 0.007
High mass-to-volume ratio
No 84.3 Reference Reference
Yes 104.8 1.241 (0.918–1.677) 0.160 1.303 (0.940–1.807) 0.112
LA area
Per 1-unit increase 1.042 (1.024–1.061) 0.001 1.013 (0.992, 1.034) 0.235
Enlarged LA Area
No 59.8 Reference Reference
Yes 119.2 1.983 (1.445–2.722) 0.001 1.470 (1.029, 2.101) 0.034
Diastolic dysfunction
Grade 0 75.8 Reference Reference
Grade 1 64.3 0.851 (0.522–1.388) 0.518 0.673 (0.402–1.128) 0.133
Grade 2 95.7 1.261 (0.823–1.933) 0.287 1.027 (0.660–1.600) 0.905
Grade 3 205.1 2.662 (1.355–5.231) 0.005 1.461 (0.726–2.941) 0.288
Heart failure end point
LV mass/HT2.7
Per 1-unit increase 1.031 (1.018–1.044) 0.001 1.025 (1.011–1.039) 0.001
LV hypertrophy
No 32.4 Reference Reference
Yes 70.2 2.145 (1.434–3.209) 0.001 1.901 (1.223–2.955) 0.004
LV mass/volume ratio
per 10unit increase 1.412 (1.121–1.779) 0.004 1.487 (1.141–1.937) 0.003
High mass-to-volume ratio
No 34.9 Reference Reference
Yes 44.6 1.275 (0.810–2.006) 0.295 1.431 (0.871–2.351) 0.157
LA area
Per 1-unit increase 1.066 (1.041–1.092) 0.001 1.036 (1.008–1.065) 0.011
Enlarged LA area
No 16.3 Reference Reference
Yes 56.7 3.521 (2.003–6.189) 0.001 2.264 (1.243–4.124) 0.008
Diastolic dysfunction
Grade 0 27.9 Reference Reference
Grade 1 23.5 0.851 (0.386–1.874) 0.688 0.775 (0.340–1.673) 0.488
Grade 2 42.7 1.567 (0.810–3.029) 0.182 1.227 (0.621–2.422) 0.556
Grade 3 83.9 3.095 (1.115–8.596) 0.030 1.500 (0.527–4.268) 0.447
*Covariates in the adjusted model included: Log NT-proBNP, age, diabetes mellitus, hospitalization for worsening heart failure
within 6 months preceding randomization, COPD or asthma, neutrophils, and ejection fraction.
LV indicates left ventricular; BSA, body surface area; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; CI, confidence
interval; LA, left atrial; and HT, height.
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patients enrolled in I-PRESERVE were very well compen-
sated, ambient LV diastolic pressures at the time of the
baseline echocardiogram were expected to be only mildly
increased. On the other hand, these patients were expected to
have a long history of variably increased LV diastolic
pressures, especially during exercise, activity, and periods of
decompensation. These increases, over the long term, would
be reflected in increased LA size. Therefore, it seems reason-
able that the best diastolic function prognostic index was LA
size.
Systolic Properties
Overall, the average values of all of the indices used to
reflect LV systolic properties for the HFPEF patients
studied in the I-PRESERVE echocardiographic substudy
fell within the normal ranges presented in Table 2. These
results were concordant with previous studies of patients
with HFPEF.13,14,18,19 However, these data should not be
interpreted to indicate that there are no abnormalities in any
single systolic index in any individual patient with HFPEF.
For example, the velocity of long-axis shortening (S) fell
below the lower limit partition value in 14% of the HFPEF
patients in our study. A small percentage of our patients also
had decreased values of other systolic properties, including
7% of the patients with an ejection fraction 50%. In
addition, no measurements of systolic parameters were made
during exercise or stress. It has been suggested that abnor-
malities in arterial stiffness and ventricular-vascular coupling
may be abnormal in HFPEF. In the current study, whereas
indices of systolic stiffness (Ees) and arterial stiffness (Ea)
were both increased, the ratio Ees/Ea, an index of ventricu-
lar-vascular coupling, fell within the normal range in our
patients with HFPEF.
Relationship Between Structure/Function
and Morbidity/Mortality
The I-PRESERVE echo substudy is the largest randomized
clinical trial to be able to provide prognostic information in
patients with HFPEF that relates morbidity and mortality to
cardiac structure and diastolic function. Recently, Komajda et
al used 58 demographic, clinical, and biological variables in
a multivariable Cox proportional hazard regression model to
examine morbidity and mortality in the HFPEF patients
studied in I-PRESERVE.34 Seven clinical variables, Log
NT-proBNP, age, diabetes mellitus, hospitalization for heart
failure within 6 months preceding randomization, chronic
lung disease, log neutrophil count, and ejection fraction, were
the strongest multivariable predictors of morbidity and mor-
tality outcomes. In the current echo substudy, these 7 clinical
variables were added to the multivariable model used to
examine the predictive value of echocardiogram-derived
structural and functional characteristics. Left ventricular
mass, LVH, LA area, LA enlargement, and the mass/volume
ratio, independent of these 7 clinical variables, were found to
Figure 2. The presence of LVH was associated with an increased cumulative event rate of the primary study end point (A) and the
heart failure end point (B) in patients with HFPEF. The presence of an increased LA area was associated with increased cumulative
event rate of the primary study end point (C) and the heart failure end (D) in patients with HFPEF. The presence of diastolic dysfunction
grade 3 increased cumulative event rate of the primary study end point (E) and the heart failure end point (F) in patients with HFPEF.
LVH indicates left ventricular hypertrophy; LA, left atrial.
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be predictive of morbidity and mortality in HFPEF patients.
Therefore, using clinical variables plus echo variables of
structure and diastolic function should enable identification
of a population of HFPEF patients who are at increased risk
of developing mortal and morbid events. The utility of
diastolic function grade was limited in the current study. This
may reflect the limitation that some patients could not be
placed in a specific grade, were indeterminate, and reduced
the sample size for analysis.
Within different studies, there are significant differences in
the prevalence of structural remodeling and abnormalities in
function and their relationship to clinical outcomes in patients
with HFPEF that appear to be based on the specific popula-
tions examined. Each population studied has some advan-
tages and some disadvantages. Taken together, the aggregate
data allow characterization of patients with HFPEF and some
limited insights into underlying pathophysiology. However,
pathophysiological mechanisms, beyond those examined in
and shown to have importance in the current analysis, may
play a role in HFPEF patients. For example, the prevalence of
structural remodeling and abnormalities in function in
HFPEF patients enrolled from populations at the time of
hospitalization for acute decompensated heart failure will
differ from those of patients enrolled as outpatients with
compensated heart failure. Prevalence will differ depend-
ing on the specific nature of the inclusion and exclusion
criteria, the geographic location, age, sex, and racial mix of
the enrolled population. Several studies illustrate these
points.14,15,17–25,35–37
Klapholz et al examined 619 patients from the New York
Heart Failure Consortium that were hospitalized with acute
decompensated heart failure.35 Some of the patients enrolled
had valvular heart disease, 15% had severe valvular heart
disease, and 75% had some valvular heart disease. Kla-
pholz reported 5 echocardiographic measurements: LV ejec-
tion fraction, LV mass, right ventricular systolic pressure, and
LV end-diastolic and end-systolic dimension. In this study,
82% of the patients had LVH. These structural and functional
measurements were not examined with respect to clinical
outcome. By contrast, I-PRESERVE examined patients who
had compensated HFPEF and who were outpatients at the
time of enrollment. Valvular heart disease was excluded from
I-PRESERVE; 28 parameters of structure and function were
examined, and 4 of these were associated with clinical
outcome.
Four publications from the Olmsted County Study reported
aspects of the structural and functional changes in 244
patients with HFPEF.15,18,36,37 This epidemiological cohort
found similar structural abnormalities in their HFPEF patients
and also related pulmonary artery systolic pressure, LV
midwall fractional shortening, and ejection fraction to sur-
vival. Although the demographics of the Olmsted County
patients were similar to those of the current study, there were
important differences in Methods that serve to extend the
findings in the Olmsted studies. I-PRESERVE examined 3
times the sample size of the Olmsted County studies and
related structural and functional parameters to mortality,
morbidity, and a comprehensive heart failure end point, and
all end points were adjudicated by a blinded end-points
committee using standardized definitions of these mortality
and morbidity end points.
The Candesartan in Heart Failure: Assessment of Reduc-
tion in Mortality and Morbidity Echocardiographic Substudy
(CHARMES) is the only other randomized clinical trial
involving patients with HFPEF studied echocardiograph-
ically.17 There is good concordance in prevalence of struc-
tural and functional findings between the 312 subjects in
CHARMES and the 745 subjects enrolled in I-Preserve.
Persson et al found a similar prevalence of LVH, LA
enlargement, and diastolic dysfunction compared to the
current study. Person et al also found a significant association
between diastolic dysfunction and outcome (increased hazard
of death/heart failure hospitalization). There are however,
significant differences in the demographic characteristics in
CHARM versus I-Preserve, described in detail in McMurray
et al that demonstrates that I-Preserve subjects were more
concordant with epidemiological studies of patients with
HFPEF.38 The echocardiograms in CHARMES were per-
formed 14 months after randomization. In addition,
CHARMES only examined the relationship of diastolic dys-
function to outcome whereas I-PRESERVE also examined
relationships between LV mass, geometry and LA size.
Potential Application of Measurements of Cardiac
Structure and Function in HFPEF Diagnosis
and Management
Heart failure is a clinical syndrome; therefore, the diagnosis
of heart failure is based on clinical symptoms and signs that
indicate increased diastolic filling pressures, decreased car-
diac output, or both. However, symptoms and signs of heart
failure lack specificity and can be confused with other
comorbidities such as aging, obesity, deconditioning, and
pulmonary and venous disease. Therefore, the presence of
objective evidence indicating increased diastolic filling pres-
sures and/or decreased cardiac output have been used to
support this clinical diagnosis. Among the methods used to
provide this objective evidence, measurements of structural
remodeling and abnormal function have proven efficacy in
patients with heart failure and a reduced ejection fraction.
Similar structural and functional abnormalities have been
sought for patients with HFPEF. The current study suggests
that the presence of LVH, concentric remodeling, LA en-
largement, and diastolic dysfunction could be used to support
the diagnosis of heart failure in patients with HFPEF. Al-
though these findings on echocardiography would not be
obligatory criteria to diagnose HFPEF, the absence of any
evidence of structural remodeling or abnormal diastolic
function would place the diagnosis in doubt. All 745 patients
in the current study had at least 1 of the following findings:
LVH, concentric remodeling, LA enlargement, and diastolic
dysfunction. These findings serve to support already pro-
posed diagnostic criteria for HFPEF and should be used as
inclusion criteria in future clinical studies.1–5 In addition, the
current study suggests that changes in cardiac structure and
function contribute prognostic information to patients with
HFPEF. Finally, the correction of abnormal LV structure and
function in HFPEF may constitute reasonable therapeutic
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targets to reduce morbidity and mortality in patients with
HFPEF.
Sources of Funding
The I-PRESERVE trial and the echocardiographic substudy were
funded by Bristol-Myers Squibb and Sanofi-aventis.
Disclosures
Drs Zile, Gottdiener, and Carson report receiving consulting fees
from Bristol-Myers Squibb and Sanofi-aventis. Dr McMurray re-
ports receiving support from Bristol-Myers Squibb (to Glasgow
University) for his work on this trial. Dr Komajda reports receiving
consulting fees from Bristol-Myers Squibb and Servier and lecture
fees from Sanofi-aventis. Dr McKelvie reports receiving consulting
fees and lecture fees from Bristol-Myers Squibb and Sanofi-aventis.
S.J. Hetzel reports being employed by the Statistical Data Analysis
Center at the University of Wisconsin Madison, which conducted the
statistical analysis for this trial that was supported by Bristol-Myers
Squibb and Sanofi-Aventis. Dr Massie reports receiving grant
support and consulting fees from Bristol-Myers Squibb and
Sanofi-aventis.
References
1. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats
TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW,
and Yancy CW. 2009 focused update: ACCF/AHA guidelines for the
diagnosis and management of heart failure in adults: a report of the
American College of Cardiology Foundation/American Heart Association
Task Force on Practice Guidelines: developed in collaboration with the
International Society for Heart and Lung Transplantation. Circulation.
2009;119:1977–2016.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray J, Ponikowski P,
Poole-Wilson P, Stro¨mberg A, van Veldhuisen D, Atar D, Hoes A, Keren
A, Mebazaa A, Nieminen M, Priori S, Swedberg K. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2008: the
Task Force for the Diagnosis and Treatment of Acute and Chronic Heart
Failure 2008 of the European Society of Cardiology. Developed in col-
laboration with the Heart Failure Association of the ESC (HFA) and
endorsed by the European Society of Intensive Care Medicine (ESICM).
Eur Heart J. 2008;29:2388–2442.
3. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal
ejection fraction: an inconvenient truth! J Am Coll Cardiol. 2010;55:
526–537.
4. Paulus WJ, Tscho¨pe C, Sanderson JE, Rusconi C, Flachskampf FA,
Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira
AF, Borbe´ly A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B,
Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart
failure: a consensus statement on the diagnosis of heart failure with
normal left ventricular ejection fraction by the Heart Failure and Echo-
cardiography Associations of the European Society of Cardiology. Eur
Heart J. 2007;28:2539–2550.
5. Yturralde RF, Gaasch WH. Diagnostic criteria for diastolic heart failure.
Prog Cardiovasc Dis. 2005;47:314–319.
6. Carson P, Massie BM, McKelvie R, McMurray J, Komadja M, Zile MR,
Ptaszynska A, Frangin G, for the I-PRESERVE Investigators. The Irbe-
sartan in Heart Failure With Preserved Systolic Function (I-PRESERVE)
trial: rationale and design. J Card Fail. 2005:11;576–585.
7. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile
MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A.
Irbesartan in patients with heart failure and preserved ejection fraction.
N Engl J Med. 2008;359:2456–2467.
8. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB,
Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M,
McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE;
I-PRESERVE Investigators. Mode of death in patients with heart failure
and a preserved ejection fraction: results from the Irbesartan in Heart
Failure With Preserved Ejection Fraction Study (I-PRESERVE) trial.
Circulation. 2010;121:1393–1405.
9. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA,
Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A. Recom-
mendations for the evaluation of left ventricular diastolic function by
echocardiography. Am Soc Echocardiogr. 2009;22:107–133.
10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka
PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD,
Spencer KT, Sutton MSJ, Stewart WJ. Recommendations for chamber
quantification: a report from the American Society of Echocardiography’s
Guidelines and Standards Committee and the Chamber Quantification
Writing Group, developed in conjunction with the European Association
of Echocardiography, a branch of the European Society of Cardiology.
J Am Soc Echocardiogr. 2005;18:1440–1463.
11. Gottdiener JS, Kitzman DW, Aurigemma GP, Arnold AM, Manolio TA.
Left atrial volume, geometry, and function in systolic and diastolic heart
failure of persons 65 years of age (the Cardiovascular Health Study).
Am J Cardiol. 2006;97:83–89.
12. Gaasch WH, Delorey DE, Sutton MGSJ, Zile MR. Patterns of structural
and functional remodeling of the left ventricle in chronic heart failure.
Am J Cardiol. 2008;102:459–462.
13. Baicu CF, Zile MR, Aurigemma GP, Gaasch WH. Left ventricular sys-
tolic performance, function, and contractility in patients with diastolic
heart failure. Circulation. 2005;111:2306–2312.
14. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD,
Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metalloprotei-
nases/tissue inhibitors of metalloproteinases: relationship between
changes in proteolytic determinants of matrix composition and structural,
functional, and clinical manifestations of hypertensive heart disease.
Circulation. 2006;113:2089–2096.
15. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo
VT, Meverden RA, Roger VL. Systolic and diastolic heart failure in the
community. JAMA. 2006;296:2209–2216.
16. Munagala VK, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR,
Redfield MM. Association of newer diastolic function parameters with
age in healthy subjects: a population-based study. J Am Soc Echo-
cardiogr. 2003;16:1049–1056.
17. Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, O¨ stergren
J, McKelvie RS, for the Investigators of the CHARM Echocardiographic
Substudy—CHARMES. Diastolic dysfunction in heart failure with pre-
served systolic function: need for objective evidence: results from the
CHARM Echocardiographic Substudy–CHARMES. J Am Coll Cardiol.
2007;49:687–694.
18. Lam CSP, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR,
Kass DA, Redfield MM. Cardiac structure and ventricular-vascular
function in persons with heart failure and preserved ejection fraction from
Olmsted County, Minnesota. Circulation. 2007;115:1982–1990.
19. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH,
Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure
with preserved ejection fraction versus nonfailing hypertensive left ven-
tricular hypertrophy in the urban Baltimore community: the role of atrial
remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198–207.
20. Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG,
Marburger CT, Brosnihan B, Morgan TM, Stewart KP. Pathophysiolog-
ical characterization of isolated diastolic heart failure in comparison to
systolic heart failure. JAMA. 2002;288:2144–2150.
21. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann
K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tscho¨pe C.
Role of Left Ventricular Stiffness in Heart Failure With Normal Ejection
Fraction. Circulation. 2008;117:2051–2060.
22. Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U,
Weitmann K, Hoffmann W, Poller W, Schultheiss HP, Pauschinger M,
Tscho¨pe C. Utility of Doppler echocardiography and tissue Doppler
imaging in the estimation of diastolic function in heart failure with normal
ejection fraction: a comparative Doppler-conductance catheterization
study. Circulation. 2007;116:637–647.
23. Fischer M. Baessler A. Hense HW, Hengstenberg C, Muscholl M,
Holmer S, Do¨ring A, Broeckel U, Riegger G, Schunkert H. Prevalence of
left ventricular diastolic dysfunction in the community: results from a
Doppler echocardiographic-based survey of a population sample. Eur
Heart J. 2003;24:320–328.
24. Abhayaratna WP, Marwick TH, Smith WT, Becker NG. Characteristics
of left ventricular diastolic dysfunction in the community: an echocar-
diographic survey. Heart. 2006;92:1259–1264.
25. van Heerebeek L, Borbe´ly A, Niessen HWM, Bronzwaer JGF, van der
Velden J, Stienen GJM, Linke WA, Laarman GJ, Paulus WJ. Myocardial
structure and function differ in systolic and diastolic heart failure.
Circulation. 2006;113:1966–1973.
26. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D,
Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A,
Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, for the HYVET
2500 Circulation December 6, 2011
 by guest on June 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Study Group. Treatment of hypertension in patients 80 years of age or
older. N Engl J Med. 2008;358:1887–1898.
27. The ALLHAT officers and coordinators for the ALLHAT Collaborative
Research Group. Major outcomes in high-risk hypertensive patients ran-
domized to angiotensin-converting enzyme inhibitor or calcium channel
blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997.
28. Poulter NR, Dobson JE, Sever PS, Dahlo¨f B, Wedel H, Campbell NRC,
on behalf of the ASCOT Investigators. Baseline Heart Rate, Antihyper-
tensive Treatment, and Prevention of Cardiovascular Outcomes in
ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll
Cardiol. 2009;54:1154–61.
29. Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlo¨f B, Devereux
RB. Impact of left ventricular geometry on prognosis in hypertensive
patients with left ventricular hypertrophy (the LIFE study). Eur J Echo-
cardiogr. 2008;9:809–815.
30. Sharp ASP, Tapp RJ, Thom SAM, Francis DP, Hughes AD, Stanton AV,
Zambanini A, O’Brien E, Chaturvedi N, Lyons S, Byrd S, Poulter NR,
Sever PS, Mayet J, on behalf of the ASCOT Investigators. Tissue Doppler
E/E ratio is a powerful predictor of primary cardiac events in a hyper-
tensive population: an ASCOT substudy. Eur Heart J. 2010;31:747–752.
31. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P,
Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine
S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST
Investigators. A calcium antagonist vs a non-calcium antagonist hyper-
tension treatment strategy for patients with coronary artery disease: the
International Verapamil-Trandolapril Study (INVEST): a randomized
controlled trial. JAMA. 2003;290:2805–2816.
32. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Pur-
kayastha D, Lacourcie`re Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh
SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP; Valsartan In
Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin
receptor blockade and antihypertensive drugs on diastolic function in
patients with hypertension and diastolic dysfunction: a randomised trial.
Lancet. 2007;369:2079–2087.
33. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua
T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B,
Zanchetti A; VALUE Trial Group. Outcomes in hypertensive patients at
high cardiovascular risk treated with regimens based on valsartan or
amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–2031.
34. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska
A, Zile MR, Demets D, Massie BM. Factors associated with outcome in
heart failure with preserved ejection fraction: findings from the Irbesartan
in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).
Circ Heart Fail. 2011;4:27–35.
35. Klapholz M, Maurer M, Lowe AM, Messineo F, Meisner JS, Mitchell J,
Kalman J, Phillips RA, Steingart R, Brown EJ Jr., Berkowitz R, Mos-
kowitz R, Soni A, Mancini D, Bijou R, Sehhat K, Varshneya N, Kukin M,
Katz SD, Sleeper LA, Le Jemtel TH; New York Heart Failure Con-
sortium. Hospitalization for heart failure in the presence of a normal left
ventricular ejection fraction: results of the New York Heart Failure
Registry. J Am Coll Cardiol. 2004;43:1432–1438.
36. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Con-
tractility and ventricular systolic stiffening in hypertensive heart disease:
insights into the pathogenesis of heart failure with preserved ejection
fraction. J Am Coll Cardiol. 2009;54:410–418.
37. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield
MM. Pulmonary hypertension in heart failure with preserved ejection
fraction: a community-based study. J Am Coll Cardiol. 2009;53:
1119–1126.
38. McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska
A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved
ejection fraction: clinical characteristics of 4133 patients enrolled in the
I-PRESERVE trial. Eur J Heart Fail. 2008;10:149–156.
CLINICAL PERSPECTIVE
The purpose of this study was to examine the prevalence and pattern of structural remodeling and alterations in function
present in patients with heart failure and a preserved ejection fraction (HFPEF) and to determine whether there was an
association among changes in cardiac structure, function, morbidity, and mortality. An echocardiographic substudy of the
Irbesartan in Heart Failure with Preserved Ejection Fraction trial (I-PRESERVE) enrolled 745 patients. Structural
remodeling and diastolic dysfunction was present in the majority of patients with HFPEF. Structural remodeling and
diastolic dysfunction predicted clinical outcomes. Increased left ventricular mass, mass/volume ratio, and left atrial size
were independently associated with an increased risk of morbidity and mortality. These findings may be pivotal to the
development of improved diagnostic criteria and prognostic assessment of patients with HFPEF. For example, the inclusion
of measurements of left ventricular mass, geometry, and diastolic function could be added to the diagnostic criteria for
HFPEF and could be used to predict the risk of morbidity and mortality in patients with HFPEF. With these data, studies
could be developed to test the hypothesis that the reversal of the changes in left ventricular structure and function would
result in reduced morbidity and mortality in patients with HFPEF. Taken together, these findings serve to enhance our
understanding of the pathophysiology underlying clinical heart failure in these patients with HFPEF.
Go to http://cme.ahajournals.org to take the CME quiz for this article.
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SUPPLEMENTAL MATERIAL
Figure Legend for Supplemental Figure:
The presence of left ventricular hypertrophy (LVH) was associated with a 
decreased survival rate of the primary study endpoint (Panel A) and the heart failure 
endpoint (Panel B) in patients with HFPEF.
The presence of an increased left atrial area was associated with a decreased 
survival rate of the primary study endpoint (Panel C) and the heart failure endpoint 
(Panel D) in patients with HFPEF.
The presence of diastolic dysfunction grade 3 decreased the survival rate of the 
primary study endpoint (Panel E) and the heart failure endpoint (Panel F) in patients 
with HFPEF.
Supplemental Table: Association Between Baseline Indices of Diastolic Function and Clinical Outcomes 
 
Primary Endpoint 
 Univariate Analysis Multivariable Analysis 2 
Variable HR (95% C.I.)  P-value HR (95% C.I.) P-value 
 
E 1.007 (1.003, 1.012) < 0.001 0.999 (0.995, 1.004) 0.724 
E/A 1.321 (1.170, 1.491) < 0.001 0.992 (0.846, 1.163) 0.918 
E’ 1.046 (1.005, 1.090) 0.029 1.016 (0.973, 1.061) 0.468 
E/E’ 1.014 (0.985, 1.044) 0.349 0.981 (0.949, 1.015) 0.264 
IVRT 0.998 (0.992, 1.005) 0.574 1.004 (0.998, 1.011) 0.220 
DT 0.998 (0.996, 1.000) 0.028 0.999 (0.997, 1.001) 0.433 
     
 
Heart Failure Endpoint     
 Univariate Analysis  Multivariate Analysis 
Variable HR (95% CI)  P-value HR (95% CI) P-value 
 
E 1.013 (1.007, 1.019) < 0.001 1.004 (0.997, 1.010) 0.275 
E/A 1.421 (1.221, 1.654) < 0.001 1.055 (0.855, 1.303) 0.615 
E’ 1.093 (1.035, 1.155) 0.001 1.040 (0.978, 1.107) 0.209 
E/E’ 1.002 (0.954, 1.052) 0.949 0.977 (0.926, 1.031) 0.394 
IVRT 0.994 (0.984, 1.004) 0.252 1.002 (0.992, 1.012) 0.683 
DT 0.996 (0.993, 0.999)  0.006 0.998 (0.995, 1.001) 0.208 
 
Abbreviations: DT = mitral valve deceleration time, IVRT = isovolumic relaxation time, E = peak early diastolic filling 
velocity, A = peak late diastolic filling velocity during atrial contraction, E’ = mitral lateral annular tissue velocity during 
early filling, HR = hazard ratio, CI = confidence intervals. 
2 Covariates in the adjusted model included: Log NT-proBNP, age, Diabetes Mellitus, hospitalization for worsening heart 
failure within 6 months preceding randomization, COPD or asthma, neutrophils, and ejection fraction. 
